TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

The HER2 receptor modulates downstream signaling by forming homodimers and heterodimers with other members of the HER family. For patients with HER2-positive breast cancer, Trastuzumab, an anti-HER2 monoclonal antibody as first-line therapy has shown significant survival benefits. However, the devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yayun, Gao, Huanyao, Zhang, Huan, John, August, Zhu, Xiujuan, Shivaram, Suganti, Yu, Jia, Weinshilboum, Richard M., Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417995/
https://www.ncbi.nlm.nih.gov/pubmed/35864174
http://dx.doi.org/10.1038/s41388-022-02415-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417995/
https://www.ncbi.nlm.nih.gov/pubmed/35864174
http://dx.doi.org/10.1038/s41388-022-02415-6

Ejemplares similares